Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.

Gadiot, Jules; Hooijkaas, Anna I; Deken, Marcel A; Blank, Christian U

Gadiot, Jules; Hooijkaas, Anna I; Deken, Marcel A; Blank, Christian U.

Afiliação

Gadiot J; Department of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Hooijkaas AI; Department of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Deken MA; Department of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Blank CU; Department of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands ; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Onco Targets Ther ; 6: 1649-58, 2013.

Article em En | MEDLINE | ID: mdl-24348046

Palavras-chave

BRAF; MEK; melanoma; skin toxicity; trametinib; vemurafenib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Idioma: En Revista: Onco Targets Ther Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google